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Abstract
Sheep are often subjected to painful procedures and thus they need to be treated with analgesics.
Nevertheless, knowledges about pharmacokinetic features of these drugs in this species are poor. The
aim of this study was to evaluate plasma behaviour of cimicoxib in sheep after a single oral adminis-
tration at two different dose rates (4 and 6 mg/kg). Maximum plasma concentrations of cimicoxib
were equal to 273.78 (median value; range 189.00-567.32) and 565.01 (range 308.27-822.59) ng/mL
after treatment with 4 and 6 mg/kg, respectively. The time of maximum concentration (Tmax) was
achieved between 4 and 10 hours following treatment at the lower dose, and between 6 and 10 hours
after the administration of the higher dose, with one sheep achieving the concentration peak at 0.75
hours.
The slow absorption and the great individual variability in plasma concentration, probably due to
ruminal effects, suggest that cimicoxib is not suitable for oral treatment in sheep.
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Introduction
Sheep are frequently submitted to painful pro-
cedures, such as castration, mulesing and tail-docking,
or can be affected by painful pathologies, such as mas-
titis and footrot (Stubsjøen et al. 2009). Moreover,
this species is commonly used as an experimental ani-
mal model for particularly invasive surgeries (Coulter
et al. 2009).
Few analgesic drugs are registered for sheep. Sev-
eral countries allow the use of drugs licensed for
others species, but this off-label use is often limited by
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the paucity of knowledge regarding the phar-
macokinetics, efficacy and residue depletion of the
drug in this animal species. Another limitation to pain
management in sheep is the difficulty in administering
injectable drugs; an oral analgesic drug administered
with feed would simplify pain treatment in sheep
(Marini et al. 2015).
Nonsteroidal anti-inflammatory drugs (NSAIDs)
are a large class of drugs used as analgesics in various
animal species. The analgesic efficacy of this class of
drugs has been reported in sheep suffering from foot-
rot or undergoing castration and tail-docking (Welsh
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and Nolan 1995, Small et al. 2014). NSAIDs may in-
volve adverse side effects, especially related to the
gastrointestinal tract. In recent decades, it has been
suggested that a preferential selectivity of these drugs
towards COX-2 enzymes could be associated with
a minor incidence of this adverse side effect (Hari-
rforoosh et al. 2013). Consequently, a new class of
drugs named coxibs, selective COX-2 inhibitors, has
appeared on the market. Cimicoxib belongs to this
group and is licensed for oral use as an anti-inflamma-
tory and analgesic drug in dogs.
Potentially, this drug could be efficiently used in
species other than the dog like the sheep, even if the
absence of a value of Maximum Residue Limit would
limit the use to experimental animals and sheep in
wool production. However, the pharmacokinetic and
pharmacodynamic differences among animal species,
especially between ruminants and monogastric spe-
cies, require studies to elucidate the behaviour of the
drug in the systemic circulation and its efficacy in the
destination species.
The aim of this study was to evaluate the phar-
macokinetics of cimicoxib after oral administration in
sheep at two different dose rates (4 and 6 mg/kg). The
choice to test higher doses of cimicoxib than that rec-
ommended for dogs (2 mg/kg), followed the knowl-
edge that sheep ruminal microflora, by metabolising
part of the drugs, could reduce their bioavailability
(Baggot and Brown 1998). In a recent study, car-
profen, flunixin and ketoprofen were administered
orally to sheep at a dose two times higher than that
reported for intravenous administration in previous
studies, in order to avoid the potential reduction of
the bioavailability operated by the ruminal environ-
ment (Marini et al. 2015). The administration of
cimicoxib in large animals has been reported only in
the equine species (horses and donkeys) (Kim et al.
2014, Kim et al. 2015). In both studies, the drug was
orally dosed at 5 mg/kg, as plasma concentrations of
cimicoxib appeared to be very low following a pilot
study conducted in horses, where 2 mg/kg were
administered.
Materials and Methods
Six Sarda ewes, weighing between 33-54 kg, were
enrolled in the study, which was approved by the Bi-
oethical Committee of the University of Perugia (pro-
tocol number: 2013-034), in accordance with the EC
Council Directive 86/609 EEC on the protection of
animals used for experimental and other scientific
purposes.
Ewes, considered healthy on the basis of clinical
examination and biochemical profile, were randomly
divided in two groups (three subjects/group) and allo-
cated to two indoor pens 5 days before the study, in
order to provide a sufficient time of acclimation.
A balling gun was used to treat sheep orally with
two different doses (4 and 6 mg/kg) of cimicoxib
(Cimalgex 80 mg, Vetoquinol, Lure, France), accord-
ing to a cross-over design (2 X 2 Latin square), with
a washout period of 2 weeks between the two treat-
ments. The drug was administered after 20 hours of
fasting, and 4 hours after the treatment the animals
were fed commercial pelleted concentrate and
meadow hay. Water was available ad libitum for the
entire experimental period.
Blood samples were collected at prefixed time
points (before treatment and after 0.25, 0.5, 0.75, 1,
1.5, 2, 4, 6, 8, 10 and 24 hours) from the jugular vein.
Blood was placed in lithium heparinised tubes and
plasma obtained after centrifugation was frozen and
maintained at -80oC until the analysis. The plasma
concentrations of cimicoxib were assessed using a pre-
viously published analytical method (Giorgi et al.
2013), and briefly revalidated in sheep plasma.
The Cmax and Tmax values were obtained from the
observed data and AUCs by linear trapezoidal rules.
Results
Following treatment with 4 mg/kg of cimicoxib, the
drug was detectable in the systemic circulation from
1 hour post administration in three animals, 1.5 hours
in one subject and 4 hours in the last two sheep of the
group. The Cmax (273.78 ng/mL, median value) was
achieved between 4-10 hours post administration; the
concentrations then dropped gradually, and cimicoxib
was still detectable in four up to 6 animals at 24 hours.
Following treatment with 6 mg/kg of cimicoxib, the
drug started to be detectable in plasma between 0.25
and 2 h. The Cmax (565.01 ng/mL, median value) was
achieved at 8 and 10 hours post administration in two
and three animals, respectively. The last subject of the
group presented the first detectable drug plasma con-
centration at 0.25 hours, the peak concentration
(536.08 ng/mL) at 0.75 hours, a concentration drop
(52.04 ng/mL) at 4 hours and an important secondary
peak (404.13 ng/mL) at 6 hours. A double peak was
also observed in two animals treated with 6 mg/kg.
Figure 1 shows the mean cimicoxib concentrations
vs. time profiles following the two treatments.
Table 1 resumes the Cmax, Tmax and AUC0-last
values obtained following oral administration of
cimicoxib at the two dose rates. No other phar-
macokinetic parameters were calculated, due to the
lack of sufficient available points needed to determine
the terminal phase.
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Fig. 1. Mean plasma concentration of cimicoxib following oral administration at 4 mg/kg and 6 mg/kg in six sheep. Bars represent
Standard Deviation.
Table 1. Tmax, Cmax and AUCs values calculated after oral administration of cimicoxib at 4 mg/Kg and 6 mg/kg in six sheep.
Parameter 4 mg/kg median value (range) 6 mg/kg median value (range)
Tmax (h) 6 (4-10) 9 (0.75-10)
Cmax (ng/mL) 273.78 (189.00-567.32) 565.01 (308.27-822.59)
AUC0-last (ng/mL*h) 2957.71 (1626.36-6771.86) 8680.47 (1951.38-11281.99)
AUC0-last: area under concentration-time curve; Cmax = Maximum observed concentration; Tmax = Time of maximum observed
concentration.
Discussion
Cimicoxib appeared in the systemic circulation in
a variable amount of time, ranging from 1 to 4 hours
in sheep treated with 4 mg/kg and from 0.25 to
2 hours after administration of 6 mg/kg. The Tmax was
obtained at a median value of 6 and 9 hours after
administration of 4 and 6 mg/kg, respectively. A poss-
ible cause of the slow rate of absorption of cimicoxib
in sheep could be the dilution of the drug in the large
volume of ruminal fluids (Baggot and Brown 1998).
A very slow absorption after oral administration in
sheep was also observed for another NSAID,
Meloxicam, which achieved the Cmax at 19 hours
(Stock et al. 2013). Another explanation for the long
time required to obtain the Cmax might be a possible
binding of cimicoxib to the hay residues in the rumen.
Even if sheep were fasted for several hours, it is
known that the rumen is never completely empty. An-
other study also suggested that cimicoxib may bind
with feed, and observed a delayed Cmax after oral ad-
ministration of cimicoxib in fed with respect to fasted
horse (Kim et al. 2015). Other NSAIDs (phenyl-
butazone and flunixin) have also been previously hy-
pothesised to bind with hay (Lees et al. 1988a).
The increase of the Cmax obtained following the ad-
ministration of 6 mg/kg of cimicoxib compared to the
value observed after the 4 mg/kg treatment was directly
proportional to the increase in the dose. However,
a large variability among sheep was observed in both
treatments, as attested by the standard deviation shown
in Fig. 1. This individual variability could be due to
different amounts of fibrous feed remaining in the ru-
men at the time of administration. This condition may
also be responsible for the secondary peaks observed in
some animals: while one part of the drug is absorbed
into the bloodstream, another part may bind to feed in
the rumen and subsequently untie from the hay due to
the fermentative process and be adsorbed to produce
a secondary peak (Lees et al. 1988b). As in the dog
cimicoxib is mainly excreted through the bile (EMA
2011), it is also possible to hypothesise that the second-
ary peak could be the consequence of enterohepatic
circulation due to biliary excretion in sheep.
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The AUC0-last value obtained after the administra-
tion of 6 mg/kg is greater than the value expected with
the dose increase, when compared to the value ob-
tained after treatment with the lower dose. An overes-
timated AUC might have been calculated after treat-
ment with the higher dose due to a paucity of samp-
ling data in the elimination phase of the curve
(Toutain and Bousquet-Melou 2004): in fact, with
a Tmax obtained between 8 and 10 hours in the major-
ity of the subjects, only one or two useful sampling
times were available to delineate the final phase of the
curve.
Another limitation of this study is the absence of
the intravenous treatment useful to define the bi-
oavailability of cimicoxib after oral administration, but
this drug is scarcely soluble in water and an injectable
formulation is not currently available.
No current data are available on the efficacy of
the treatment with cimicoxib in sheep and no studies
have been performed to establish the selectivity of this
drug on the COXs in sheep. An efficacious plasma
concentration of cimicoxib, above or equal to 216
ng/mL, has been reported in dogs (EMA 2011). This
concentration was achieved in sheep at approximately
3 and 5 hours, and maintained for 20 and 4 hours after
administering cimicoxib at 6 and 4 mg/kg, respectively
(Fig. 1). If the same plasma concentration would be
effective in sheep, the drug could be administered
3 hours before the painful procedure at the dose of
6 mg/kg, and its effect would last for over 20 hours.
However, the great variability in the absorption of
cimicoxib in sheep suggests that the treatment is un-
predictable. Therefore, the drug is probably not suit-
able for oral treatment in ovine.
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